News

Results of a systematic review including two large trials have confirmed that adding a drug called abiraterone to standard long-term hormone therapy helps men with prostate cancer that has spread to live longer. These results, from the STOPCaP study, were published this week in the European Journal of Cancer. Abiraterone is a type of hormone therapy currently licensed to treat prostate cancer that has spread and has stopped responding to standard hormone therapy. Both trials tested using it earlier, in men starting long-term standard hormone therapy for the first time. Overall, the results showed that adding abiraterone to standard hormone therapy reduced the risk of death by 38%. This means that after three years, 69 out of 100 men who received abiraterone were alive compared to 55 out of 100 men who just had standard hormone therapy. Abiraterone also reduces the risk of prostate cancer getting worse by 55%. This means that after three years, 58 out of 100 men who received abirater ...

For the purposes of the STAMPEDE trial, an online PSA doubling time value calculator has been linked to allow sites to calculate this PSA velocity easier. We hope with the linking of this calculator it will be easier for you to track a patient’s PSA record. For more details see the tools and training section here. ...

The Stampede team are pleased to announce that the "transdermal oestradiol comparison" (Arm L) was activated today (20/06/2017) at 9am. We have 40 sites ready to randomise and we will continue to re-open sites as quickly as possible. Congratulations to all sites that were ready on Day 1! If you are yet to receive a green light activation you cannot randomise. To complete the activation process look here. ...

Giving the drug abiraterone alongside standard hormone therapy improves the survival of men with high-risk or advanced prostate cancer, according to results from the STAMPEDE trial, published in the New England Journal of Medicine on 3 June 2017. In the “abiraterone comparison” in STAMPEDE, 957 men who were randomised to receive standard of care (hormone therapy with or without radiotherapy) were compared to 960 men who were randomised to receive abiraterone plus prednisolone plus standard of care (hormone therapy with or without radiotherapy). Men in the abiraterone group had four abiraterone tablets and one prednisolone tablet a day. Abiraterone (also known as abiraterone acetate, or Zytiga) is a type of hormone therapy that works in a different way to standard hormone therapy. Abiraterone is currently licensed to treat prostate cancer that has spread and has stopped responding to standard hormone therapy. STAMPEDE tested using it earlier, when men were starting standard hormone th ...

For the purposes of the STAMPEDE trial, a PSA progression value calculator has been created to allow sites to calculate a unique threshold PSA value for biochemical failure for each patient, referred to as the PSA progression value. In the past, research staff have received Progression Letters or contacted the STAMPEDE trial team to obtain this value. However the PSA progression calculator allows research staff to determine the Progression Value themselves, by entering the patient’s PSA results from randomisation to week 24, and printing a copy of the calculation for the patient’s records. We hope with the launch of this calculator it will be easier for you to track a patient’s PSA record and progression status. Additionally we welcome any feedback or suggestions for improvement! For more details see the tools and training section here. ...